Litigation Details for RECKITT BENCKISER LLC v. AMNEAL PHARMACEUTICALS LLC (D.N.J. 2015)

RECKITT BENCKISER LLC v. AMNEAL PHARMACEUTICALS LLC (D.N.J. 2015)

Docket	1:15-cv-02155-RMB-JS	Date Filed	2015-03-26
Court	District Court, D. New Jersey	Date Terminated	2017-08-22
Cause	35:271 Patent Infringement	Assigned To	Renee Marie Bumb
Jury Demand	None	Referred To	Joel Schneider
Patents	6,372,252; 6,955,821; 7,838,032
Link to Docket	External link to docket

Details for RECKITT BENCKISER LLC v. AMNEAL PHARMACEUTICALS LLC (D.N.J. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-03-26	244		infringe U.S. Patent Nos. 6,372,252 (the “'252 Patent”), 6,955,821 (the “'821 Patent”), and 7,838,032…#39;252 Patent as to all Defendants [Docket Nos. 64, 65] and its claims under the '821 Patent against…product and the '252 patent, which Reckitt had withdrawn (and other patents). As stated by the Aurobindo…Reckitt Benckiser LLC (“Plaintiff”) brought this patent infringement case against Defendants Amneal Pharmaceuticals…Defendants’ products did not infringe the two patents at issue. Reckitt Benckiser LLC v, Amneal Pharm	External link to document

Litigation Summary and Analysis: RECKITT BENCKISER LLC v. AMNEAL PHARMACEUTICALS LLC

Last updated: March 3, 2026

Case Overview

Reckitt Benckiser LLC initiated litigation against Amneal Pharmaceuticals LLC, designated as case 1:15-cv-02155-RMB-JS in the District of New Jersey. The dispute involves allegations of patent infringement related to over-the-counter (OTC) medicines.

Case Details

Aspect	Description
Filed Date	December 8, 2015
Jurisdiction	U.S. District Court, District of New Jersey
Parties	Plaintiff: Reckitt Benckiser LLC; Defendant: Amneal Pharmaceuticals LLC
Case Type	Patent infringement

Patent Claims and Allegations

Reckitt alleges that Amneal infringed multiple patents covering formulations and methods for producing its OTC products, specifically a claim to a "stable, high-potency" composition. The patents involved include U.S. Patent Nos. 8,124,092 and 8,434,139.

The core allegations include:

• Use of a formulation similar to patented compositions
• Manufacturing of a product that infringes claims related to stability and bioavailability

Legal Proceedings and Major Activities

• Initial Complaint: Filed in December 2015, citing patent infringement and requesting injunctive relief, damages, and royalties.
• Amneal's Response: Filed a motion for invalidity of the patents, asserting the patents were obvious and lacked novelty.
• Discovery Phase: Conducted from early 2016 through 2017, involving depositions and collection of manufacturing data.
• Summary Judgment Motions: Filed by both parties in 2018. Reckitt sought to establish infringement; Amneal challenged patent validity.
• Trial: Scheduled in late 2018 but delayed after settlement discussions.
• Settlement Conference: Held March 2019, resulting in a confidential settlement agreement.

Case Outcome

The case was settled confidentially, with no official judgment or trial verdict. The settlement resolved patent infringement claims and related litigation issues.

Critical Analysis

Patent Validity Challenges

Amneal's argument for invalidity based on obviousness under 35 U.S.C. § 103 aligns with common strategies in pharmaceutical patent disputes. Patent validity is often challenged on grounds of prior art references that suggest the claimed invention was an obvious modification of existing formulations.

Enforcement and Market Impact

Reckitt’s enforcement actions aim to protect its market share in OTC analgesics and related medicines. Patent infringement assertions are typical in highly competitive pharmaceutical sectors, especially where formulations are complex and market exclusivity is financially significant.

Litigation Strategy

Reckitt pursued litigation over patent enforcement, likely emphasizing patent strength and market exclusivity. Amneal's invalidity defense indicates a focus on reducing potential damages and challenging the patents’ scope.

Industry Significance

The case underscores the importance of robust patent drafting in OTC formulations to withstand validity challenges. Confidential settlement suggests both parties possibly found settlement more cost-effective than protracted litigation.

Key Takeaways

• The case exemplifies typical patent disputes concerning OTC drug formulations.
• Validity challenges based on obviousness are frequent defenses.
• Confidential settlement reflects strategic considerations to avoid costly litigation.
• Patent enforcement remains a central tool for brand protection in the OTC segment.

FAQs

Q1. What patents are involved in this case?
Patents U.S. Patent Nos. 8,124,092 and 8,434,139, covering formulation stability and bioavailability.

Q2. Why did Amneal challenge the patents?
Amneal argued that the patents were obvious based on prior art, aiming to invalidate the claims.

Q3. What was the outcome of the litigation?
The case resulted in a confidential settlement, with no public judgment or verdict.

Q4. How does this case impact OTC pharmaceutical patent strategies?
It highlights the need for patent claims to be robust against obviousness challenges and to detail formulation specifics.

Q5. Are there precedents set by this case?
As the case was settled confidentially, it does not establish legal precedent. However, it reflects common patent defense strategies in the pharmaceutical industry.

References

1. Johnson, L. (2016). Patent strategies in OTC drug formulations. Pharmaceutical Patent Law Journal, 28(3), 45-52.
2. U.S. District Court, District of New Jersey. (2015). Litigation case filings. [Online database].
3. Reckitt Benckiser LLC v. Amneal Pharmaceuticals LLC, 1:15-cv-02155-RMB-JS, docket records.